OncoMatch/Clinical Trials/NCT06300528
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
Is NCT06300528 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Pemigatinib for relapsed or refractory b-cell non-hodgkin lymphoma.
Treatment: Pemigatinib — The purpose of this clinical trial is to learn if the study drug pemigatinib is effective in treating patients with relapsed or refractory B-cell non-Hodgkin lymphomas.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: fgfr inhibitor
Lab requirements
Blood counts
ANC ≥ 1000/mm3 independent of G-CSF support (no G-CSF within past 3 days), unless bone marrow involvement or splenomegaly with cytopenia (then ANC ≥ 750/mm3 allowed); Platelet count ≥ 75,000/mm3 independent of transfusion support (no transfusion within past 3 days), unless bone marrow involvement (then ≥ 50,000/mm3 allowed); Hemoglobin ≥ 8 g/dL independent of transfusion support (no transfusion within past 3 days), unless bone marrow involvement or splenomegaly with cytopenia (then ≥ 7 g/dL allowed); no evidence of myelodysplasia or hypoplastic bone marrow.
Kidney function
Estimated creatinine clearance ≥ 30 mL/min by Cockcroft-Gault formula.
Liver function
Total Bilirubin ≤ 1.5x institutional ULN or <2.5 x ULN with documented liver involvement and/or Gilbert's disease; AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional ULN; subjects with liver involvement allowed with AST and ALT ≤ 5 x ULN.
Cardiac function
No congestive heart failure NYHA Class III or IV, serious cardiac arrhythmias, unstable angina or acute coronary syndrome within 2 months, MI within 3 months, QTcF > 470 ms (unless corrected), LVEF < 40% in prior 12 months.
Adequate organ function as defined as: Hematologic: ANC ≥ 1000/mm3...; Platelet count ≥ 75,000/mm3...; Hemoglobin ≥ 8 g/dL...; Hepatic: Total Bilirubin ≤ 1.5x institutional ULN...; AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional ULN...; Renal: Estimated creatinine clearance ≥ 30 mL/min by Cockcroft-Gault formula.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Huntsman Cancer Institute at University of Utah · Salt Lake City, Utah
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06300528 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior fgfr inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages